SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Peter Silsbee who wrote (3194)12/7/1997 5:13:00 PM
From: biodoc   of 6136
 
Pardon me for trying to answer this question, but there may be several possible reasons why the full story doesn't come out in a press release or in a meeting presentation: (these are all speculations based on experience)

1) The number of patients in each dose group alone may be too small to be very confident about the percent "undetectable" in the individual group. Having to go back on a good number later could be more of a problem than not giving it up front.

2) It may be reserved for initial presentation in a peer-reviewed journal.

3) A desire to keep real and potential competitors guessing may preclude giving out any more information than the minimum required by SEC for disclosure.

4) And, of course, maybe the results aren't so good. Time will tell.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News